TherapeuticsMD (TXMD) Gross Profit (2011 - 2023)

TherapeuticsMD's Gross Profit history runs 13 years deep, the most recent figure standing at $502000.0 for Q4 2023.

• Quarterly Gross Profit fell 99.27% year-over-year to $502000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.3 million (down 98.43% YoY) and the FY2023 annual result came in at $1.3 million, down 98.1% from the prior year.
• Gross Profit was $502000.0 for Q4 2023 at TherapeuticsMD, up from -$53000.0 in the prior quarter.
• Across five years, Gross Profit topped out at $68.6 million in Q4 2022 and bottomed at -$53000.0 in Q3 2023.
• A 5-year average of $13.6 million and a median of $13.5 million in 2019 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2019 — Gross Profit surged 702.7% — and 2023, when it sank 99.27%.
• TherapeuticsMD's Gross Profit stood at $13.0 million in 2019, then soared by 30.52% to $17.0 million in 2020, then retreated by 17.98% to $13.9 million in 2021, then jumped by 391.83% to $68.6 million in 2022, then sank by 99.27% to $502000.0 in 2023.
• Business Quant data shows TXMD's Gross Profit at $502000.0 in Q4 2023, -$53000.0 in Q3 2023, and $437000.0 in Q2 2023.